Donald Trump and the Future of the Indian Pharmaceutical Industry and India-US Relations
Trump's Influence on Indian Pharma
Donald Trump’s return to the presidency could create new pathways for the Indian pharmaceutical industry. With his administration's focus on reducing dependence on Chinese supply chains, the US Biosecure Act, 2024, presents substantial opportunities for India’s drugmakers.
Impacts on India-US Relations
As Indian pharma seeks to decrease fees for new drug applications amid increasing tariffs, the partnership with the US holds potential for mutual benefit. Over 31% of India’s pharmaceutical exports are directed towards the US, establishing a vital economic connection.
Regulatory Framework Enhancements
To leverage the prospects brought by Trump's policies, enhancing regulatory frameworks will be essential. Industry veterans emphasize the need for adaptability within India’s pharmaceutical regulations to maintain a competitive edge.
Future Directions
Overall, the collaboration will foster affordable healthcare solutions globally, with India playing an indispensable role in supplying quality medicines.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.